Valneva

Renowned, peer-reviewed medical journal, The Lancet Infectious Diseases has published Phase 2 immunogenicity and safety results of an 18-month booster dose of Valneva and Pfizer’s Lyme disease vaccine candidate after primary immunisation in healthy adults in the USA. Read more here: https://lnkd.in/d95gFX7q

This month, one of the largest sporting events in the world is set to kick off in Paris, with millions of people expected to descend upon the region. While this is an exciting time that brings together people from all over the globe, such mass gatherings can pose potential public health risks, including the spread of infectious diseases transmitted by mosquitos. Read this insightful article by Dr. Juan Carlos Jaramillo, our Chief Medical Officer, on the growing risk of mosquito-borne diseases and essential preparation and prevention measures below. https://rb.gy/ekffdz #MosquitoBorneDiseases #infectiousdisease #Paris #Olympics #publichealth #AdvancingVaccinesForBetterLives

Meet the #Valneva team! Adrianne is our Global Market Access Manager. She works collaboratively with different teams, focusing on research through literature and health economic studies.  With expert team members like Adrianne, we continue to make significant progress in advancing a wide range of vaccine candidates for infectious diseases associated with significant unmet medical needs. Check out Adrianne’s interview to learn more about her role and why she enjoys working at Valneva.  #EmployeeSpotlight #Vaccines #PublicHealth #AdvancingVaccinesForBetterLives 

Valneva CMO Dr. Juan Carlos Jaramillo comments on the Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® More details here: https://ow.ly/tSbK50SsNcS

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® https://lnkd.in/dakdaghM

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of Danièle Guyot-Caparros to its Board of Directors https://ow.ly/KBRo50SqgiC

Valneva CMO Dr. Juan Carlos Jaramillo shares his thoughts on Health Canada’s approval of the world’s first chikungunya vaccine, IXCHIQ® More details here: https://ow.ly/ITtm50So9VO

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® https://lnkd.in/dHqehBc7

Huge congratulations to all our incredible winners at last night's European Mediscience Awards 2024, sponsored by HSBC Innovation Banking. We hope you had a wonderful evening celebrating and we look forward to seeing you all again next year! #EMA24 MoonLake Immunotherapeutics (NASDAQ: MLTX) Valneva Tubulis GmbH Brad Loncar BiotechTV Autolus Therapeutics Ruth McKernan Karim Bitar Convatec Zealand Pharma

🏆 We’re honored to have won Breakthrough of the Year for our chikungunya vaccine at the European Mediscience Awards 2024!